Onkológia 3/2015

Gastrointestinal stromal tumors and some new treatment options

Gastrointestinal tumors are the most common mesenchymal tumors of the intestinal tract with 20 cases a year in Slovak republic. With the introduction of imatinib the treatment of GIST was transformed because imatinib achieves response rate of 45 % to 50 %, with median survival rates 60 months. Complete surgical resection is the standard treatment for localized GISTs. The standard treatment of metastatic and locally advanced GISTs is imatinib as first-line, sunitinib as second-line therapy and regorafenib as third-line treatment of patients who progressed on or intolerant to prior imatinib and sunitinib. The clinical responses observed with newer agents provide efficacious therapeutic modalities.

Keywords: gastrointestinal tumors ,imatinib, sunitinib, regorafenib, newer agents.